| Name | Cemdisiran |
|---|---|
| Synonyms |
Cemdisiran, terminal sugmodification
4,8-Dioxa-12,16-diazaheneicosanamide, 21-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-N-[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]-6-[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-6-[[12-[(2S,4R)-4-hydroxy-2-[(phosphonooxy)methyl]-1-pyrrolidinyl]-1,12-dioxododecyl]amino]-11,17-dioxo 4,8-Dioxa-12,16-diazaheneicosanamide, 21-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-N-[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]-6-[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-6 |
| Description | Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the treatment of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C78H140N11O34P |
|---|---|
| Molecular Weight | 1806.97 |